Angiographic Tool to Detect Pulmonary Arteriovenous Malformations in Single Ventricle Physiology

INTRODUCTION

Pulmonary arteriovenous malformations (PAVMs) frequently develop after superior cavopulmonary anastomosis (Glenn surgery) (1-4). Remarkably, these PAVMs can resolve after total cavopulmonary anastomosis (Fontan completion), which has led to the “hepatic factor” hypothesis: the liver makes an unknown substance that maintains the normal vascular architecture of the lungs (3, 5). Surgical and interventional strategies to redirect hepatic venous blood to affected lungs have been successful to resolve PAVMs (6-9). However, while all Glenn patients lose direct flow of “hepatic factor” to their lungs, not all Glenn patients develop clinically significant PAVMs (10).

PAVM screening of Glenn patients is fraught with technical difficulty. Intracardiac mixing prevents use of peripheral arterial PaO₂ saturation. Direct measurement of PaO₂ from pulmonary veins is not always feasible. The common screening modality (peripherally injected bubble contrast echocardiography) is technically variable, prone to false positives, and unable to detect capillary recruitment or proliferation of small caliber vessels (11-14). Meanwhile, the confirmatory test used in patients with hereditary hemorrhagic telangiectasia (computed tomography scan) has a spatial resolution of 0.15 mm, which is 10 times greater than the size of the dilated capillary vessels that could allow for positive contrast echocardiogram (14, 15). Therefore, CT may not be able to detect shunts that are due to diffuse microvascular dilation.

In light of these unresolved issues with the current tools for detection, and cognizant of the importance of detection for prognosis and clinical management, we sought to develop a screening tool that could detect changes in the pulmonary microvascular architecture. We used pulmonary angiography to define a pulmonary capillary transit time (PCTT), tracking the flow of contrast through the normal pulmonary vasculature—or through the shortcuts that PAVMs provide. This PCTT tool, applied to single ventricle patients with Glenn anatomy, was studied to determine pulmonary vascular changes that may occur in the absence of direct hepatopulmonary venous flow.

MATERIALS and METHODS

Definition of PCTT

We defined PCTT as the number of cardiac cycles between initial opacification of the distal pulmonary arteries to the earliest opacification of the major pulmonary veins, indexed to the cardiac cycle (Figure 1). The degree of opacification was not taken into account. All patients were sedated and mechanically ventilated as part of the procedure, and angiographic technique was at the discretion of the attending cardiologist. However, angiograms were only selected for analysis if the contrast was injected centrally, not in a distal pulmonary artery (Supplementary Table S1). Consequently, there is a short delay between the start of injection and the start of the PCTT.

• Download figure
• Open in new tab

Figure 1: Definition of the PCTT.

Pulmonary capillary transit time is defined as the number of cardiac cycles taken for contrast to traverse the pulmonary capillary bed. Calculation of the PCTT starts when the contrast reaches the distal major branches of the pulmonary arteries, and stops when the first visible contrast is present in the pulmonary veins.

Cardiac cycle time was obtained from simultaneous EKG recordings. When simultaneous EKG was not available, direct observation of the motion of the cardiac silhouette was used (average of five cardiac cycles; frame rate of the angiogram divided by number of frames per beat, multiplied by 60 to obtain beats per minute). PCTT was calculated for left and right lungs separately, and the average was then used for subsequent grouping and analysis.

RESULTS

PCTT is Accelerated During the Glenn Stage

The clinical characteristics of our Glenn cohort are listed in Table 1. We found that the mean PCTT of the control group (with normal cardiopulmonary vascular connections and biventricular hearts) was 3.25 (95% CI 2.9 – 3.6). Similar to the control group, the mean PCTT of the pre-Glenn and the Fontan groups were 3.53 and 3.48, respectively (Figure 2A). However, the mean PCTT of the Glenn patients was 2.37 (95% CI 2.01 – 2.73) cardiac cycles, significantly faster than all other individual groups (p<0.001). A detailed comparison of clinical characteristics at each stage is available in Supplementary Table S2.

View this table:

• View inline
• View popup
• Download powerpoint

Table 1: Study Cohort Characteristics.

Among 84 Glenn patients recruited to the study, the majority were male, situs solitus, with a single right ventricle and variable initial palliation procedures.

• Download figure
• Open in new tab

Figure 2: Loss of Direct Hepatopulmonary Blood Flow Leads to Reversible Acceleration of PCTT.

(A) There is no significant difference in the PCTT between patients with normal cardiopulmonary vascular connections and single ventricle patients in the Pre-Glenn or Fontan stage. However, the PCTT in patients with Glenn anatomy is significantly accelerated. (B) Tracking individual patients (from A) through each surgical stage shows accelerated PCTT in the Glenn that reverts to normal after restoration of direct hepatopulmonary blood flow. Two patients whose PCTT did not decrease from Pre-Glenn to Glenn are highlighted in red, and one patient whose PCTT did not increase from Glenn to Fontan is highlighted in blue. (C) Stage-to-stage difference for the individual patients shown in (B).

When individual patients were analyzed longitudinally, we found that 90% (18/20) of patients had a faster PCTT in the Glenn stage, compared to the pre-Glenn stage (Figure 2B,C). Using a linear mixed model, incorporating the correlation between repeated measurements from the same patient, we found that there is a significant decrease from pre-Glenn to Glenn (p < 0.0001) and a significant increase from Glenn to Fontan (p = 0.0002) (Table 2).

View this table:

• View inline
• View popup
• Download powerpoint

Table 2:

In our Glenn patients, there was no association between PCTT and either injection pressure, contrast dose, rate of injection, or rate of rise (Supplementary Figure S1). Additionally, there was no association between PCTT and catheter size (p=.55) or catheter type (p=.24) (Supplementary Figure S2). Similarly, in the Glenn cohort, neither peak PA pressure, mean PA pressure, transpulmonary gradient, or ventricular end-diastolic pressure correlated with PCTT (Table 3). Five independent reviewers of calculated PCTT for twenty Glenn angiograms, which yielded an ICC of 0.87 (95% CI 0.7 – 0.95, p<0.001), indicating good agreement between viewers (Supplementary Table S3).

View this table:

• View inline
• View popup
• Download powerpoint

Table 3: Relation of PCTT and Patient-Specific Factors During the Glenn Stage.

Basic physical parameters, angiographic and hemodynamic conditions, and readouts of successful alveolar gas exchange were examined using Pearson correlation for their relation to the PCTT. Parameters were highlighted in red if there was a significant correlation with PCTT. All pressure measurements are in mm Hg. Abbreviations: PA=pulmonary artery, PV=pulmonary vein, PCW=pulmonary capillary wedge, Qp=pulmonary blood flow, Qs=systemic blood flow, PVR=pulmonary vascular resistance (Woods units), SVR=systemic vascular resistance (Woods units), RUPV=right upper PV, RLPV=right lower PV, LUPV=left upper PV, LLPV=left lower PV.

DISCUSSION

This study provides the first published evidence that the pulmonary capillary transit time varies with the stage of single ventricle palliation. Our results validate the traditional teaching that, in the absence of PAVMs, contrast takes at least three cardiac cycles to travel through the pulmonary capillary bed. In 90% (n=20) of patients, PCTT accelerates in the Glenn stage. The pre-Glenn data presented in our study provides evidence that the pulmonary vasculature was not initially abnormal (with a fast PCTT). Rather, the acceleration of pulmonary capillary transit correlates with the absence of direct hepatopulmonary venous flow in this surgical stage.

PAVM detection is difficult and subject to variable limitations in the Glenn population. Diagnostic modalities of PAVM detection may be understood as attempts either to visualize the lesion (CT, magnetic resonance imaging, MRI, or pulmonary angiography), or to detect the effects of pulmonary arteriovenous shunting (pulmonary venous desaturation, contrast echocardiography [CE], 99mTc macroaggregated albumin scan). The PCTT represents a combination of these two strategies, as we visualize the effects of pulmonary arteriovenous shunting.

Peripherally-injected contrast echocardiography (CE) remains the standard screening method for PAVMs in the general population (15). CE has been used previously to show reversibility of PAVMs after reintroduction of direct hepatopulmonary venous flow, by comparing patients in the Glenn and Fontan stages (5). Recent work in Fontan patients, however, has shown that the significant majority of Fontan patients have a positive CE (12). While we suspect that their remarkably high positive rate is affected by the use of a distally placed end-hole catheter for bubble contrast injection (applying direct force to dilate the peripheral capillaries), their work does highlight the need for a new diagnostic modality that can track changes secondary to presence or absence of hepatic factor.

While our work is the first of its kind in pediatric cardiology, a single study in adult patients with hepatopulmonary syndrome defines a similar “pulmonary transit time” (PTT, time in seconds from initial injection and opacification of the main pulmonary artery to that of the left atrium) (16). Intriguingly, they report a diagnostic utility comparable to contrast echocardiography. However, they include in their transit time the portion that takes place in the large arteries, and—critically—do not account for cardiac output, thereby preventing application of their methods to pediatric patients with single ventricle heart disease and highly variable cardiac output.

By requiring a central (rather than peripheral) injection site, we reduce the likelihood of falsely accelerating the PCTT. And by not starting the transit time until contrast reaches the distal pulmonary vessels, we avoid most extra-parenchymal collateral vessels and focus analysis on the intra-parenchymal PAVMs. Indeed, in ex vivo studies of isolated, perfused lungs, the distal capillary bed was shown to be responsible for the major variations in pulmonary transit time (17).

While visual calculation of the PCTT is reliable and fast, we plan to develop an automated analysis for further ease of application. We anticipate that machine learning coupled with shadow tracking will prove effective against a background of respiratory and cardiac motion. Quantification of MR or CT-derived transit times will also be helpful, especially as their use increases for pre-Glenn evaluation (18, 19). Finally, as more data is gathered, we hope to use PCTT to create a continuous scale that could predict outcomes and pulmonary vascular complications after the Glenn and Fontan surgeries.

Conclusions

Pulmonary capillary transit time is a simple, rapid, and reproducible method to assess changes in the pulmonary vascular architecture. Our results confirm the traditional teaching that the contrast takes at least three cardiac cycles to traverse the normal pulmonary vasculature. Our longitudinal study of PCTT in single ventricle patients reinforces the hepatic factor hypothesis and shows a measurable effect of hepatic factor loss in even “normal” Glenn patients.

Financial Support

This work was supported financially by the Pediatric Scientist Development Program (NICHD K12-HD000850) and the Leducq Foundation Transatlantic Network of Excellence grant “ReVAMP— Recalibrating Mechanotransduction in Vascular Malformations” (2022–2027).

Conflicts of Interest

None

Ethical Standards

The authors assert that this work complies with the ethical standards of the relevant national guidelines and with the Helsinki Declaration of 1975, as revised in 2008, and has been approved by the University of Texas Southwestern Independent Review Board (IRB), UTSW IRB 2020-0047.